Research Context
Peptides and Pregnancy: What the Research Actually Shows
Pregnancy is an area where peptide research is almost entirely absent, yet demand for information is high. This article covers what is known from regulatory sources, what is inferred from animal data or class effects, and where the evidence gap is complete. It is organised by compound class. This is not medical advice and nothing here should be interpreted as guidance for individual decisions during pregnancy.
Important
Nothing in this article should be used to make decisions about compound use during pregnancy or when trying to conceive. The information here is a research summary. All decisions in this context require discussion with a qualified physician or obstetrician.
GLP-1 Receptor Agonists: The Clearest Warnings
This class has the strongest evidence base and the most explicit regulatory action of any peptide category in the context of pregnancy. Semaglutide, liraglutide, and tirzepatide all carry formal Pregnancy Category warnings from both the FDA and EMA, based on animal reproductive toxicology studies.
The animal data showed embryotoxicity and teratogenicity at clinically relevant doses. The proposed mechanism of harm is two-fold: GLP-1 receptor agonism slows gastric emptying and reduces caloric intake, potentially limiting nutritional availability to the developing fetus; and GLP-1 receptors are also expressed in fetal tissue, meaning the compounds do not simply act peripherally in the mother. The combination of reduced substrate delivery and direct fetal receptor engagement constitutes a plausible pathway to developmental harm, and the animal toxicology data is consistent with this model.
FDA and EMA guidance: current position
Both the FDA and EMA currently recommend discontinuing GLP-1 receptor agonists at least 2 months before attempting conception. This recommendation accounts for the long half-life of agents such as semaglutide (approximately one week) and the need for adequate clearance before the critical window of early fetal development begins.
Retatrutide, the triple agonist targeting GLP-1, GIP, and glucagon receptors, is still in Phase 3 trials. Pregnant women are excluded from these trials by protocol, so no human pregnancy data exists. Animal reproductive toxicology data for retatrutide has not been fully published. By class analogy with semaglutide and liraglutide, the precautionary position is the same: discontinue well before attempting conception, and treat any pregnancy exposure as a potential concern requiring clinical monitoring.
Growth Hormone Secretagogues
This class includes ipamorelin, CJC-1295, GHRP-2, GHRP-6, sermorelin, and MK-677 (ibutamoren). No human pregnancy data exists for any compound in this group.
The theoretical concern is significant: growth hormone and IGF-1 axes are actively involved in fetal development. These pathways regulate cell proliferation, differentiation, and organ formation across multiple critical windows during gestation. Exogenous stimulation of GH secretion during fetal development is not simply unstudied; it represents an intervention in a system that is already operating at a tightly regulated baseline for developmental purposes. The risk is plausible even in the absence of direct toxicology data.
Available animal data is limited. Most studies in this class were short-term, designed to assess efficacy rather than reproductive outcomes, and were not structured to detect teratogenicity or embryotoxicity. The absence of documented harm in these studies should not be read as evidence of safety; the studies were not designed to find it.
Position
Insufficient evidence to consider any GH secretagogue safe during pregnancy. The theoretical risk from GH/IGF-1 axis stimulation during fetal development is plausible and unstudied. Avoidance is the only defensible precautionary position.
Tissue Repair Peptides: BPC-157 and TB-500
BPC-157 and TB-500 are the two most commonly researched tissue repair peptides. Their pregnancy profiles are distinct.
BPC-157
Some animal data exists for the gastric pentadecapeptide. Rodent model studies have investigated BPC-157 in contexts that included pregnant or breeding animals without observing an obvious embryotoxic signal. However, these studies were not designed with pregnancy as a primary endpoint, doses varied across studies, and the methodology is insufficient to support any conclusion about human fetal safety. No human pregnancy data exists. BPC-157 cannot be considered safe during pregnancy based on current evidence; the data simply does not exist to make that assessment.
TB-500 (Thymosin Beta-4)
Thymosin Beta-4, the full protein from which the TB-500 fragment derives, is expressed endogenously during embryogenesis and plays a documented role in cardiac and vascular development. This is not a safety reassurance. The endogenous presence of a molecule during development does not imply that exogenous supplementation is safe: receptor saturation, off-target effects, and interference with the tightly regulated endogenous concentration are all possible. The fact that the body uses Thymosin Beta-4 during fetal development is, if anything, a reason to approach exogenous administration with additional caution during that same period.
Position
No evidence of harm has been documented for either compound in animal data, but no adequate pregnancy safety studies have been conducted for either. Insufficient data to draw any conclusion. Precautionary default is avoidance.
Melanocortin Peptides: PT-141 and Melanotan II
Melanocortin receptors (MC1R, MC3R, MC4R) are expressed during fetal development and play roles in pigmentation, immune modulation, and energy homeostasis. Compounds that activate these receptors are not biologically inert during pregnancy.
PT-141 (Bremelanotide)
PT-141 (marketed as Vyleesi) was developed and reviewed as a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Because this population overlaps with women of childbearing age, the FDA label for PT-141 explicitly contraindicates use during pregnancy. This is one of the few research peptides with a formal regulatory contraindication in this context, rather than simply an absence of data. The contraindication is based on reproductive safety data requirements built into the approval process.
Melanotan II
Melanotan II has received no formal regulatory review in any jurisdiction. There is no pregnancy data of any kind. Given the documented role of melanocortin receptors in fetal development, this is a theoretical concern without evidence to quantify it. Insufficient data; theoretical concern based on receptor biology.
Position
PT-141 is formally contraindicated during pregnancy per its FDA label. Melanotan II has insufficient data; theoretical concern based on melanocortin receptor expression in fetal tissue.
Longevity and Nootropic Peptides
This group includes epitalon, Semax, Selank, Dihexa, SS-31, and MOTS-c. Pregnancy-specific data is essentially absent for all of them.
A synthetic tetrapeptide that acts on telomerase activity. No reproductive toxicology data has been published. Telomerase is active during embryonic development; the implications of exogenous epitalon administration during this period are unknown and unstudied.
Derived from the ACTH(4-7) sequence. Animal data is minimal and not pregnancy-focused. ACTH and its analogues have known interactions with the hypothalamic-pituitary-adrenal axis, which is significantly altered during pregnancy. Pregnancy-specific data: absent.
Derived from the immunomodulatory peptide tuftsin. Animal data is limited and not designed to assess reproductive outcomes. Pregnancy-specific data: absent.
A hepatocyte growth factor (HGF) potentiator with potent pro-cognitive effects in animal models. HGF plays roles in placentation and fetal organ development. The implications of exogenous HGF potentiation during pregnancy are unknown. Pregnancy-specific data: absent.
A mitochondria-targeted antioxidant peptide. Mitochondrial function is critically important during embryogenesis; exogenous modulation has not been studied in the pregnancy context. Pregnancy-specific data: absent.
A mitochondrial-derived peptide regulating AMPK and metabolic signalling. Metabolic regulation during pregnancy is complex and tightly controlled; the effects of exogenous MOTS-c on this system during gestation are unknown. Pregnancy-specific data: absent.
Position
No evidence base exists for any compound in this class in the pregnancy context. None can be considered safe during pregnancy by default. Several have plausible theoretical concerns based on their mechanisms intersecting with active developmental pathways.
The General Principle: Absence of Evidence Is Not Evidence of Safety
For almost every research peptide covered on WikiPeptide, pregnancy studies do not exist. This is not because researchers have looked and found no risk. It is because pregnant women are excluded from clinical trials by protocol, as a standard ethical protection. The absence of documented harm is a product of the absence of study, not of reassuring data.
The precautionary default for any unstudied compound during pregnancy is avoidance. This applies across essentially all research peptides other than those with explicit regulatory review in the pregnancy context (the GLP-1 class, and PT-141). For those two classes, the regulatory position is already clear: GLP-1 agonists are not to be used during pregnancy and should be stopped well before conception is attempted; PT-141 is contraindicated during pregnancy per its FDA label.
For compounds like BPC-157, TB-500, GH secretagogues, and the longevity peptides, there is simply no data. Researchers and individuals should not interpret this article as implying these compounds are safe; the honest position is that we do not know, and the prudent clinical position is that unknown risk during pregnancy defaults to avoidance.
GLP-1 Agonists and Fertility: The Dual Role
The same mechanism that creates the pregnancy risk concerns detailed earlier in this article also explains why GLP-1 agonists have helped some women conceive. Understanding this dual role is essential for anyone managing PCOS or obesity-related reproductive dysfunction with these compounds.
In PCOS: metabolic correction restoring ovulatory function
PCOS-related infertility is driven primarily by insulin resistance and elevated androgens causing anovulation. Elevated insulin stimulates ovarian theca cells to overproduce androgens, which disrupts follicular development and prevents regular ovulation. GLP-1 agonists improve insulin sensitivity, which reduces the androgen overproduction, allowing the hypothalamic-pituitary-ovarian axis to resume normal pulsatility and follicular development. When anovulation was the barrier to conception, removing it allows pregnancy to occur. This is not a fertility drug effect; it is metabolic correction with fertility as a downstream consequence. Case series and retrospective data have documented restored menstrual cycles and unintended pregnancies in women on semaglutide and liraglutide for PCOS or weight loss, and this is now a recognised clinical phenomenon.
In obesity-related anovulation: the weight loss pathway
Obesity suppresses ovulatory function through multiple pathways including elevated oestrone from peripheral aromatisation of androgens in adipose tissue, leptin resistance, and insulin resistance. Weight loss by any means, including dietary restriction, bariatric surgery, or pharmacological treatment, can restore ovulatory cycles in women with obesity-related anovulation. GLP-1-mediated weight loss has the same effect. A woman who resumes ovulation following GLP-1 treatment is at risk of pregnancy even if her cycles were previously absent or severely irregular.
The clinical paradox: preconception planning is essential
GLP-1 agonists should be discontinued at least 2 months before attempting conception, yet they may be what enables conception to occur in the first place. This creates a specific preconception planning requirement for clinicians managing reproductive-age women on these agents: contraception discussion during treatment, education about the ovulation restoration effect, timed discontinuation with a planned washout window, and confirmation of clearance before conception attempts begin. For women with PCOS who are approaching the point of wanting to conceive, the clinical conversation should address both the fertility benefit of continued treatment and the mandatory discontinuation before conception.
Male fertility: limited data, plausible mechanism
GLP-1 receptors are expressed in testicular tissue. Obesity and metabolic syndrome impair sperm quality through mechanisms including elevated scrotal temperature, oxidative stress, and hormonal disruption from elevated oestrone. Whether GLP-1-mediated weight loss and insulin sensitisation improve male fertility parameters is suggested by limited observational data but has not been confirmed in randomised controlled trials. The biological plausibility exists, but the evidence base is insufficient to draw clinical conclusions. Male partners using GLP-1 agonists who are planning conception should discuss this with their prescribing physician, particularly given that GLP-1 receptor expression in testicular tissue means these compounds are not biologically inert in this context.
Frequently Asked Questions
Are GLP-1 peptides safe during pregnancy? +
No. GLP-1 receptor agonists including semaglutide, liraglutide, and tirzepatide carry explicit pregnancy warnings from both the FDA and EMA based on animal reproductive toxicology data showing embryotoxicity and teratogenicity at clinically relevant doses. Current regulatory guidance from both agencies is to discontinue these medications at least 2 months before attempting conception. The proposed mechanism of harm includes reduced nutritional availability to the fetus and direct GLP-1 receptor expression in fetal tissue.
When should I stop semaglutide before trying to conceive? +
Current FDA and EMA guidance recommends discontinuing semaglutide at least 2 months before attempting conception. This reflects the drug's long half-life (approximately one week) and the need for adequate clearance before the critical window of early fetal development begins. The specific timing in your individual case should be discussed with the prescribing physician, as health factors and pharmacokinetics vary.
Is BPC-157 safe during pregnancy? +
There is insufficient evidence to make that determination. Some rodent studies have used BPC-157 in breeding contexts without observing an obvious embryotoxic signal, but those studies were not designed to assess reproductive outcomes and cannot be used to support a claim of human pregnancy safety. No human pregnancy data exists for BPC-157. The absence of evidence of harm is not the same as evidence of safety. The precautionary default is avoidance during pregnancy.
Are there any peptides that are safe to use while pregnant? +
For the research peptides covered on WikiPeptide, no compound has sufficient human evidence to support use during pregnancy. The GLP-1 class carries explicit regulatory warnings. For GH secretagogues, BPC-157, TB-500, melanocortin peptides, and longevity or nootropic compounds, pregnancy-specific data is absent because pregnant women are excluded from clinical trials by protocol. The lack of safety data means these compounds cannot be considered safe by default. Any decisions in this area require a qualified healthcare provider.
What should I do if I took peptides before knowing I was pregnant? +
Disclose all compound use to your obstetrician or midwife as soon as possible, including the specific compound, approximate timing relative to conception, and route and dose if known. For GLP-1 agonists, early exposure is a documented concern and your care provider will want to monitor accordingly. For other research peptides where data is absent, the clinical approach is typically to monitor the pregnancy normally while noting the exposure in the medical record. Do not attempt to assess the risk yourself based on online sources. Your healthcare provider is the appropriate person to evaluate this in the context of your specific circumstances.
Can GLP-1 peptides help with fertility? +
In some women, yes. GLP-1 receptor agonists can restore ovulation indirectly by correcting the metabolic conditions that cause anovulation. In PCOS, improved insulin sensitivity reduces the androgen overproduction that prevents regular ovulation. In obesity-related anovulation, GLP-1-mediated weight loss has the same effect as weight loss by other means. Case series and retrospective data have documented restored menstrual cycles and unintended pregnancies in women on semaglutide and liraglutide. Critically, GLP-1 agonists carry pregnancy warnings and must be discontinued at least 2 months before attempting conception. The compound that can enable pregnancy cannot safely be continued into that pregnancy.
How do GLP-1 agonists restore ovulation in PCOS? +
PCOS-related anovulation is driven primarily by insulin resistance causing elevated ovarian androgen production. Elevated insulin stimulates ovarian theca cells to overproduce androgens, which disrupts follicular development and prevents regular ovulation. GLP-1 agonists improve insulin sensitivity and reduce circulating insulin, which in turn reduces androgen overproduction from theca cells. As androgens fall, follicular development can proceed and ovulation resume. Weight loss accompanying treatment further supports this process. This is a metabolic correction, not a direct hormonal intervention at the level of the ovary or pituitary.
Medical and Research Notice
This article is an educational research summary. It does not constitute medical advice, and nothing in it should be used to make decisions about compound use during pregnancy or when attempting to conceive. All such decisions require consultation with a qualified physician or obstetrician who is aware of your complete medical history.
The evidence landscape for peptides in pregnancy is sparse and changes as new data is published. Regulatory guidance for GLP-1 agents is reviewed periodically and may be updated. WikiPeptide is not affiliated with any pharmaceutical company, pharmacy, or clinical practice. This page reflects information available as of July 2026.
Related Pages
Semaglutide, Protocol Page
GLP-1 receptor agonist: mechanism, dosing, metabolic effects, and protocol data.
BPC-157, Protocol Page
Research profile: mechanism, tissue repair, angiogenesis, and protocol data.
TB-500, Protocol Page
Thymosin Beta-4 fragment: actin binding, healing, and anti-inflammatory properties.
PT-141, Protocol Page
Bremelanotide: melanocortin receptor agonism, sexual function research, and regulatory status.
Research and Regulatory Reference
All WikiPeptide regulatory and research context pages.